VALEANT PHARMACEUTICALS INTL I (VRX) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:VRX - CA91911K1021
23.4
-0.83 (-3.43%)
23.36
-0.04 (-0.17%)
No Fundamental Analysis report for VRX not available.
23.4
-0.83 (-3.43%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners0.13%
Inst Owner Change0%
Ins Owners1.27%
Ins Owner Change0%
Market Cap8.16B
Revenue(TTM)8.61B
Net Income(TTM)-917.00M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.91 | ||
| Fwd PE | 6.74 | ||
| P/S | 0.95 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.8 | ||
| P/tB | N/A | ||
| EV/EBITDA | 45.74 |
EPS(TTM)3.96
EY16.92%
EPS(NY)3.47
Fwd EY14.83%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS24.69
BVpS12.97
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.56% | ||
| ROE | -20.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -10.65% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.59 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | -0.29 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.98%
EPS 3YN/A
EPS 5Y-8.55%
EPS Q2Q%-68.21%
EPS Next Y-12.27%
EPS Next 2Y-4.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.51%
Revenue growth 3YN/A
Revenue growth 5Y8.34%
Sales Q2Q%-5.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
VALEANT PHARMACEUTICALS INTL I / VRX FAQ
What is the fundamental rating for VRX stock?
ChartMill assigns a fundamental rating of 3 / 10 to VRX.
What is the valuation status for VRX stock?
ChartMill assigns a valuation rating of 6 / 10 to VALEANT PHARMACEUTICALS INTL I (VRX). This can be considered as Fairly Valued.
How profitable is VALEANT PHARMACEUTICALS INTL I (VRX) stock?
VALEANT PHARMACEUTICALS INTL I (VRX) has a profitability rating of 5 / 10.
What is the expected EPS growth for VALEANT PHARMACEUTICALS INTL I (VRX) stock?
The Earnings per Share (EPS) of VALEANT PHARMACEUTICALS INTL I (VRX) is expected to decline by -12.27% in the next year.
Is the dividend of VALEANT PHARMACEUTICALS INTL I sustainable?
The dividend rating of VALEANT PHARMACEUTICALS INTL I (VRX) is 0 / 10 and the dividend payout ratio is 0%.